Fulcrum plummets 50% after scrapping lead sickle-cell drug on FDA concerns

Investing.com Gold reports: Fulcrum plummets 50% after scrapping lead sickle-cell drug on FDA concerns. Full body text was unavailable at ingest time, so this brief is based on headline context.